Prognostic power of molecular subtypes in inflammatory breast cancer: A multicentric study.

e11546 Background: Inflammatory breast cancer (IBC) represents up to 15% of all breast cancer in North Africa. However, this form is poorly characterized and its subtypes defined by hormonal receptor (HR) and HER2 status have not been well studied yet.In this study, we compared pathological complete response (pCR) rates, progression free survival (PFS) and overall survival (OS) by HR/HER2 subtype in IBC North African population. Methods: We retrospectively reviewed data of sixty six non metastatic IBC patients from Morocco, Egypt and Tunisia. All patients had received neoadjuvant sequential chemotherapy: 3 cycles of anthracyclines based regimen then 3 cycles of taxanes based regimen. Trastuzumab was associated to taxanes in erb2 overexpressed cases. Patients included had available information on estrogen receptor, progesterone receptor, HER2 status and Mib1 score. Kaplan-Meier method was used to estimate median PFS and OS durations from the time of first cycle of chemotherapy. The Cox proportional hazards...